FDA extending review of Biogen’s Hemophilia B treatment drug
(Reuters) – Biogen Idec Inc on Monday said the U.S. Food and Drug Administration will extend by three months its deadline for reviewing the company’s experimental long-acting medicine for hemophilia. Biogen, which is developing the drug in partnership with Swedish Orphan Biovitrum AB, said it had provided the FDA additional information related to validation of […]